NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
University of Florida
University of Michigan Rogel Cancer Center
Yonsei University
University of Miami
Lund University Hospital